Published in Immunity on October 01, 2002
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum (2009) 3.34
Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J (2004) 3.32
Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr D Biol Crystallogr (2012) 3.05
Non-canonical NF-κB signaling pathway. Cell Res (2010) 3.03
Functions of NF-kappaB1 and NF-kappaB2 in immune cell biology. Biochem J (2004) 3.01
Essential role of RelA Ser311 phosphorylation by zetaPKC in NF-kappaB transcriptional activation. EMBO J (2003) 2.97
The noncanonical NF-κB pathway. Immunol Rev (2012) 2.57
Nurselike cells express BAFF and APRIL, which can promote survival of chronic lymphocytic leukemia cells via a paracrine pathway distinct from that of SDF-1alpha. Blood (2005) 2.37
Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum (2012) 2.21
Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther (2008) 2.15
Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest (2006) 2.05
Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00
Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. Proc Natl Acad Sci U S A (2003) 1.96
BAFF controls B cell metabolic fitness through a PKC beta- and Akt-dependent mechanism. J Exp Med (2006) 1.93
Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med (2003) 1.85
Inhibition of the TWEAK/Fn14 pathway attenuates renal disease in nephrotoxic serum nephritis. Clin Immunol (2012) 1.74
Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev (2011) 1.70
The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis. Arthritis Res Ther (2008) 1.68
BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med (2005) 1.67
Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival. Blood (2007) 1.64
Epstein-Barr virus latent membrane protein 1 activation of NF-kappaB through IRAK1 and TRAF6. Proc Natl Acad Sci U S A (2003) 1.60
The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol (2012) 1.49
NIBP, a novel NIK and IKK(beta)-binding protein that enhances NF-(kappa)B activation. J Biol Chem (2005) 1.47
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood (2006) 1.43
Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J Immunol (2006) 1.43
The IkappaB kinase complex and NF-kappaB act as master regulators of lipopolysaccharide-induced gene expression and control subordinate activation of AP-1. Mol Cell Biol (2004) 1.39
B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels. Arthritis Res Ther (2006) 1.36
NF-kappaB activation by protein kinase C isoforms and B-cell function. EMBO Rep (2003) 1.30
Proteolysis of NF-kappaB1 p105 is essential for T cell antigen receptor-induced proliferation. Nat Immunol (2008) 1.30
BAFF activates Akt and Erk through BAFF-R in an IKK1-dependent manner in primary mouse B cells. Proc Natl Acad Sci U S A (2008) 1.29
The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys (2008) 1.23
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A (2004) 1.21
Neutrality of the canonical NF-kappaB-dependent pathway for human and murine cytomegalovirus transcription and replication in vitro. J Virol (2004) 1.21
Innate control of B cell responses. Trends Immunol (2011) 1.21
Respiratory syncytial virus influences NF-kappaB-dependent gene expression through a novel pathway involving MAP3K14/NIK expression and nuclear complex formation with NF-kappaB2. J Virol (2005) 1.13
Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets. J Exp Med (2009) 1.13
A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res (2010) 1.12
The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis (2006) 1.11
BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. Blood (2009) 1.10
B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice. J Immunol (2011) 1.08
Crosstalk between PKCzeta and the IL4/Stat6 pathway during T-cell-mediated hepatitis. EMBO J (2004) 1.07
TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One (2010) 1.07
NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood (2007) 1.07
Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE. J Biomed Biotechnol (2012) 1.06
Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity. Arthritis Rheum (2010) 1.05
Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. Blood (2007) 1.05
Constitutive production of NF-kappaB2 p52 is not tumorigenic but predisposes mice to inflammatory autoimmune disease by repressing Bim expression. J Biol Chem (2008) 1.00
NF-kB inhibitor blocks B cell development at two checkpoints. Med Immunol (2004) 1.00
Tax-independent constitutive IkappaB kinase activation in adult T-cell leukemia cells. Neoplasia (2004) 0.99
B-cell antigen-receptor signalling in lymphocyte development. Immunology (2003) 0.99
Autosomal-dominant B-cell deficiency with alopecia due to a mutation in NFKB2 that results in nonprocessable p100. Blood (2014) 0.99
TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J (2006) 0.99
Context-specific BAFF-R signaling by the NF-κB and PI3K pathways. Cell Rep (2013) 0.99
NF-kappaB2 is required for the control of autoimmunity by regulating the development of medullary thymic epithelial cells. J Biol Chem (2006) 0.98
Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity (2010) 0.98
Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 0.98
BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis. PLoS One (2011) 0.97
TRAF6 is required for generation of the B-1a B cell compartment as well as T cell-dependent and -independent humoral immune responses. PLoS One (2009) 0.96
NIK prevents the development of hypereosinophilic syndrome-like disease in mice independent of IKKα activation. J Immunol (2012) 0.96
The role of nuclear factor-kappaB essential modulator (NEMO) in B cell development and survival. Proc Natl Acad Sci U S A (2003) 0.95
FcgammaRIIB signals inhibit BLyS signaling and BCR-mediated BLyS receptor up-regulation. Blood (2008) 0.93
Future prospects in biologic therapy for systemic lupus erythematosus. Nat Rev Rheumatol (2013) 0.93
Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci (2012) 0.92
Aging murine B cells have decreased class switch induced by anti-CD40 or BAFF. Exp Gerontol (2006) 0.92
BAFF inhibition: a new class of drugs for the treatment of autoimmunity. Exp Cell Res (2011) 0.91
Unexpected development of autoimmunity in BAFF-R-mutant MRL-lpr mice. Immunology (2006) 0.91
Systemic autoimmunity in BAFF-R-mutant A/WySnJ strain mice. Eur J Immunol (2008) 0.90
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys. Am J Pathol (2006) 0.89
The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther (2008) 0.88
A primary immunodeficiency characterized by defective immunoglobulin class switch recombination and impaired DNA repair. J Exp Med (2007) 0.87
A Complex Relationship between TRAF3 and Non-Canonical NF-κB2 Activation in B Lymphocytes. Front Immunol (2013) 0.87
Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. Arthritis Rheum (2013) 0.87
The current status of targeting BAFF/BLyS for autoimmune diseases. Arthritis Res Ther (2004) 0.87
SLE--systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther (2003) 0.86
NF-κB as a target for oncogenic viruses. Curr Top Microbiol Immunol (2011) 0.86
New roles for the BLyS/BAFF family in antigen-experienced B cell niches. Cytokine Growth Factor Rev (2014) 0.86
Loss of negative feedback control of nuclear factor-kappaB2 activity in lymphocytes leads to fatal lung inflammation. Am J Pathol (2010) 0.86
Analysis of the regulatory role of BAFF in controlling the expression of CD21 and CD23. Mol Immunol (2006) 0.86
B-cell-activating factor inhibits CD20-mediated and B-cell receptor-mediated apoptosis in human B cells. Immunology (2008) 0.85
TWEAK/Fn14 and Non-Canonical NF-kappaB Signaling in Kidney Disease. Front Immunol (2013) 0.85
BAFF mediates splenic B cell response and antibody production in experimental Chagas disease. PLoS Negl Trop Dis (2010) 0.84
Impairment of Mature B Cell Maintenance upon Combined Deletion of the Alternative NF-κB Transcription Factors RELB and NF-κB2 in B Cells. J Immunol (2016) 0.84
Irradiation up-regulates CD80 expression through two different mechanisms in spleen B cells, B lymphoma cells, and dendritic cells. Immunology (2004) 0.83
Murine BAFF-receptor residues 168-175 are essential for optimal CD21/35 expression but dispensable for B cell survival. Mol Immunol (2009) 0.82
The Role of Ubiquitination in TWEAK-Stimulated Signaling. Front Immunol (2013) 0.82
Activation of NF-κB by the Kaposi's sarcoma-associated herpesvirus K15 protein involves recruitment of the NF-κB-inducing kinase, IκB kinases, and phosphorylation of p65. J Virol (2014) 0.82
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
Altered BAFF-receptor signaling and additional modifier loci contribute to systemic autoimmunity in A/WySnJ mice. Eur J Immunol (2009) 0.81
Manipulating B cell homeostasis: a key component in the advancement of targeted strategies. Arch Immunol Ther Exp (Warsz) (2008) 0.80
Global T cell dysregulation in non-autoimmune-prone mice promotes rapid development of BAFF-independent, systemic lupus erythematosus-like autoimmunity. J Immunol (2008) 0.79
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther (2015) 0.78
Protein kinase Cδ promotes transitional B cell-negative selection and limits proximal B cell receptor signaling to enforce tolerance. Mol Cell Biol (2014) 0.78
Hyperglycemia exacerbates burn-induced liver inflammation via noncanonical nuclear factor-κB pathway activation. Mol Med (2012) 0.78
Expression and localization of rabbit B-cell activating factor (BAFF) and its specific receptor BR3 in cells and tissues of the rabbit immune system. Dev Comp Immunol (2009) 0.78
A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma. Int J Mol Sci (2014) 0.78
NF-κB-inducing kinase increases renal tubule epithelial inflammation associated with diabetes. Exp Diabetes Res (2011) 0.78
Expression of TNF-α, APRIL and BCMA in Behcet's disease. J Immunol Res (2014) 0.76
Critical role of B cell lymphoma 10 in BAFF-regulated NF-κB activation and survival of anergic B cells. J Immunol (2012) 0.76
CD137 is induced by the CD40 signal on chronic lymphocytic leukemia B cells and transduces the survival signal via NF-κB activation. PLoS One (2013) 0.76
Cryopyrin activates the inflammasome in response to toxins and ATP. Nature (2006) 18.74
Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature (2004) 14.80
Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med (2011) 13.18
De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature (2004) 12.41
Non-canonical inflammasome activation targets caspase-11. Nature (2011) 8.85
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell (2007) 8.48
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet (2010) 7.11
Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature (2006) 6.56
Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell (2008) 5.37
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature (2011) 5.32
Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science (2013) 5.06
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Innate immunity against Francisella tularensis is dependent on the ASC/caspase-1 axis. J Exp Med (2005) 5.00
The Birc1e cytosolic pattern-recognition receptor contributes to the detection and control of Legionella pneumophila infection. Nat Immunol (2006) 4.70
Absent in melanoma 2 is required for innate immune recognition of Francisella tularensis. Proc Natl Acad Sci U S A (2010) 4.57
Therapeutic antibody targeting of individual Notch receptors. Nature (2010) 4.56
Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med (2010) 4.52
A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med (2009) 4.20
Probable person to person transmission of novel avian influenza A (H7N9) virus in Eastern China, 2013: epidemiological investigation. BMJ (2013) 4.17
Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature (2009) 4.12
Kinase RIP3 is dispensable for normal NF-kappa Bs, signaling by the B-cell and T-cell receptors, tumor necrosis factor receptor 1, and Toll-like receptors 2 and 4. Mol Cell Biol (2004) 4.05
Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature (2003) 3.96
A family cluster of infections by a newly recognized bunyavirus in eastern China, 2007: further evidence of person-to-person transmission. Clin Infect Dis (2011) 3.91
DUBA: a deubiquitinase that regulates type I interferon production. Science (2007) 3.88
Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. J Cell Biol (2009) 3.85
Human Streptococcus suis outbreak, Sichuan, China. Emerg Infect Dis (2006) 3.65
Inflammasomes: guardians of cytosolic sanctity. Immunol Rev (2009) 3.58
Effect of socioeconomic status on treatment and mortality after stroke. Stroke (2002) 3.44
Caspase-11 increases susceptibility to Salmonella infection in the absence of caspase-1. Nature (2012) 3.40
Regulation of NF-kappaB-dependent lymphocyte activation and development by paracaspase. Science (2003) 3.28
Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science (2004) 3.28
A NOD2-NALP1 complex mediates caspase-1-dependent IL-1beta secretion in response to Bacillus anthracis infection and muramyl dipeptide. Proc Natl Acad Sci U S A (2008) 3.27
Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc Natl Acad Sci U S A (2012) 3.21
Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol (2012) 3.18
The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell (2007) 3.13
Signaling in innate immunity and inflammation. Cold Spring Harb Perspect Biol (2012) 3.11
Liver is the major source of elevated serum lipocalin-2 levels after bacterial infection or partial hepatectomy: a critical role for IL-6/STAT3. Hepatology (2015) 3.10
Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects. Science (2013) 3.10
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res (2009) 3.07
Long-term efficacy of a hepatitis E vaccine. N Engl J Med (2015) 3.00
Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS One (2009) 2.98
Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol (2010) 2.88
Structure of C3b in complex with CRIg gives insights into regulation of complement activation. Nature (2006) 2.69
Loss of the tumor suppressor BAP1 causes myeloid transformation. Science (2012) 2.69
Pannexin-1 is required for ATP release during apoptosis but not for inflammasome activation. J Immunol (2011) 2.67
Preparation and evaluation of recombinant severe fever with thrombocytopenia syndrome virus nucleocapsid protein for detection of total antibodies in human and animal sera by double-antigen sandwich enzyme-linked immunosorbent assay. J Clin Microbiol (2011) 2.63
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
Evolution of TNF signaling mechanisms: JNK-dependent apoptosis triggered by Eiger, the Drosophila homolog of the TNF superfamily. Curr Biol (2002) 2.54
TSPAN12 regulates retinal vascular development by promoting Norrin- but not Wnt-induced FZD4/beta-catenin signaling. Cell (2009) 2.53
K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell (2010) 2.52
USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell (2011) 2.51
Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity (2003) 2.51
Identification of a novel homotypic interaction motif required for the phosphorylation of receptor-interacting protein (RIP) by RIP3. J Biol Chem (2001) 2.45
Live-animal markets and influenza A (H7N9) virus infection. N Engl J Med (2013) 2.43
Mitochondrial reactive oxygen species drive proinflammatory cytokine production. J Exp Med (2011) 2.35
Sex differences in carotid endarterectomy outcomes: results from the Ontario Carotid Endarterectomy Registry. Stroke (2003) 2.28
Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol (2011) 2.27
Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol (2009) 2.26
An aluminum-activated citrate transporter in barley. Plant Cell Physiol (2007) 2.24
Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis. Science (2014) 2.23
Pathologic complete response to neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma is associated with a better prognosis. Ann Diagn Pathol (2011) 2.23
Manipulation of host cell death pathways during microbial infections. Cell Host Microbe (2010) 2.21
Signaling to NF-kappaB: regulation by ubiquitination. Cold Spring Harb Perspect Biol (2010) 2.15
Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc (2013) 2.14
Physical activity and changes in weight and waist circumference in midlife women: findings from the Study of Women's Health Across the Nation. Am J Epidemiol (2004) 2.11
Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerg Infect Dis (2006) 2.07
Mice lacking the CARD of CARMA1 exhibit defective B lymphocyte development and impaired proliferation of their B and T lymphocytes. Curr Biol (2003) 2.04
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Analysis of the activation status of Akt, NFkappaB, and Stat3 in human diffuse gliomas. Lab Invest (2004) 2.02
Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med (2014) 2.01
Deubiquitinases in the regulation of NF-κB signaling. Cell Res (2010) 2.00
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol (2011) 1.95
Primate-specific microRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling. Hepatology (2011) 1.93
Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates. J Immunol (2009) 1.93
Engineering and structural characterization of a linear polyubiquitin-specific antibody. J Mol Biol (2011) 1.93
Deubiquitinase USP37 is activated by CDK2 to antagonize APC(CDH1) and promote S phase entry. Mol Cell (2011) 1.92
Phosphorylation of NLRC4 is critical for inflammasome activation. Nature (2012) 1.92
WNK4 enhances the degradation of NCC through a sortilin-mediated lysosomal pathway. J Am Soc Nephrol (2009) 1.87
GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet (2012) 1.86
Yersinia virulence factor YopJ acts as a deubiquitinase to inhibit NF-kappa B activation. J Exp Med (2005) 1.85
Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol (2011) 1.85
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res (2005) 1.84
COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature (2011) 1.83
Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice. Hepatology (2010) 1.82
The Putative RNA-dependent RNA polymerase RDR6 acts synergistically with ASYMMETRIC LEAVES1 and 2 to repress BREVIPEDICELLUS and MicroRNA165/166 in Arabidopsis leaf development. Plant Cell (2005) 1.80
Regulation of NF-κB by deubiquitinases. Immunol Rev (2012) 1.78